gefitinib has been researched along with Colorectal Cancer in 91 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 59 (64.84) | 29.6817 |
| 2010's | 30 (32.97) | 24.3611 |
| 2020's | 2 (2.20) | 2.80 |
| Authors | Studies |
|---|---|
| Casadebaig, F; De Giorgi, F; Gissot, A; Gravier, D; Hou, G; Ichas, F; Lartigue, L; Pédeboscq, S; Pometan, JP; Rey, C | 1 |
| Chang, Y; Cheng, H; Ding, K; Lu, J; Lu, X; Luo, J; Ren, X; Tu, Z; Zhang, L; Zhang, Q | 1 |
| Kong, L; Li, Y; Liu, H; Liu, X; Wang, LL; Yuan, F; Zhang, L; Zhang, Y; Zuo, Z | 1 |
| Ao, J; Hu, J; Liang, S; Liu, Y; Luo, X; Pang, Y; Wei, L; Xiao, B; Yang, J; Zhang, Y | 1 |
| Chang, TC; Chang, WJ; Changou, CA; Chen, YR; Cheng, RH; Chin, YT; Chiu, SJ; Chu, HR; Davis, PJ; Hastuti, ED; Huang, TY; Li, ZL; Lin, HY; Liu, FC; Mousa, SA; Pan, YS; Shih, YJ; Wang, K; Wang, SH; Whang-Peng, J; Wu, A | 1 |
| Collard, TJ; Greenhough, A; Gupta, B; Legge, DN; Morgan, RG; Mortensson, E; Williams, AC | 1 |
| Bi, F; Bi, NX; Gong, QY; Liu, BS; Liu, Q; Nie, YZ; Tang, QL; Xia, HW; Zhou, JT; Zhou, S | 1 |
| Chang, TC; Changou, CA; Chen, YR; Chin, YT; Davis, PJ; Liao, YM; Lin, HY; Nana, AW; Shih, A; Shih, YJ; Stain, SC; Wang, K; Wang, LS; Wang, SH; Whang-Peng, J; Wu, CH; Yang, YS | 1 |
| Berry, CT; Brady, DC; Davis, CI; Feng, Z; Freedman, BD; Glynn, RA; He, X; Hua, X; Katona, BW; Liu, Y; Ma, J; Matkar, S; Paulosky, KE; Szigety, KM; Wang, H; Wu, Y | 1 |
| Ju, Q; Shao, H; Shi, H; Xu, R; Zhu, J | 1 |
| Clevers, H; Joosten, SPJ; Mizutani, T; Pals, ST; Spaargaren, M | 1 |
| Cassidy, J; Hochster, H | 1 |
| Aristei, C; Calzuola, M; Cecchini, D; Contavalli, P; Falzetti, F; Marini, V; Palumbo, I; Piattoni, S; Valentini, V; Vecchio, FM | 1 |
| Jiao, S; Liu, T; Xie, X; Yang, J; Zhang, G | 1 |
| Ge, H; Guan, L; Liu, X; Sun, M; Sun, X; Xiao, Q; Zhang, H; Zhang, Y | 1 |
| Fujita, M; Hara, M; Ito, Y; Kanemitsu, Y; Kondo, E; Nakanishi, H; Nakata, S; Tanaka, H; Yatabe, Y | 1 |
| Boeck, S; Bruns, CJ; Camaj, P; Gamba, S; Giessen, C; Haertl, C; Heinemann, V; Laubender, RP; Modest, DP; Stintzing, S; Wang, Y; Zhao, Y | 1 |
| Essapen, S; Fan, Z; Khelwatty, SA; Modjtahedi, H; Seddon, AM | 1 |
| Aasrum, M; Brusevold, IJ; Christoffersen, T; Sandnes, D; Tveteraas, IH; Ødegård, J | 1 |
| Han, BW; Hou, BX; Li, YW; Luo, XY; Ma, ZK; Nie, PP; Shi, XP; Zou, ZZ | 1 |
| Chen, X; He, L; Li, M; Li, Q; Li, T; Xu, X; Zhang, D | 1 |
| Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M | 1 |
| Bissonnette, M; Koetsier, JL; Kunte, DP; Roy, HK; Wali, RK | 1 |
| Fennell, DA; Johnston, PG; Kelly, DM; Kyula, J; Longley, DB; Stokesberry, S; Van Schaeybroeck, S | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Bovio, H; de Sande González, L; García-Foncillas, J; García-Girón, C; García-López, JL; Lacave, AJ; Peláez, I; Reboredo, M; Valladares, M; Viéitez, JM | 1 |
| Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U | 1 |
| Wörmann, B | 1 |
| Fenning, CS; Fenton, A; Johnston, PG; Kyula, JN; Longley, DB; Sasazuki, T; Shirasawa, S; Van Schaeybroeck, S | 1 |
| Chen, Y; Ding, Z; Li, J; Liang, H; Pan, F; Peng, Q; Ran, L; Yang, L; Zhao, X | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Coffey, RJ; Liebler, DC; Manning, HC; Myers, MV | 1 |
| Albanell, J; Bellmunt, J; Bellosillo, B; Bosch, F; Crespo, M; Dalmases, A; Gallen, M; Himmelbauer, H; Iglesias, M; Marsters, S; Minoche, A; Montagut, C; Pairet, S; Rovira, A; Salido, M; Serrano, S; Seshagiri, S; Settleman, J; Somasekar, S; Tsai, SP | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Bepler, G; Chen, W; Ghosh, D; Norkin, M; Raghunathan, TE; Sargent, DJ | 1 |
| Essapen, S; Khelwatty, SA; Modjtahedi, H; Seddon, AM | 1 |
| Ranson, M | 1 |
| Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
| Benson, AB; O'dwyer, PJ | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Cohen, RB | 1 |
| Lorusso, PM | 1 |
| Schiller, JH | 1 |
| Douglass, EC | 1 |
| Batist, G; Daneshmand, M; Goss, G; Hirte, HW; Lorimer, IA; Major, P; Matthews, S; Miller, WH; Parolin, DA; Seymour, L; Stewart, D | 1 |
| Avitto, FM; Beltrami, V; Cirolla, VA; Conte, S; Covotta, A; Covotta, L; Giarnieri, E; Luzzatto, L; Marino, G; Midiri, G; Vecchione, A | 1 |
| Yamada, K; Yamaguchi, S; Yamamura, T | 1 |
| Kanzawa, F; Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T; Tsukiyama, S; Ueda, Y | 1 |
| Adenis, A; Peyrat, JP | 1 |
| Damjanov, N; Meropol, NJ | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Von Pawel, J | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Barnard, GF; Inoue, H; Ishii, H; Ishikawa, K; Mimori, K; Mori, M; Ohta, M; Utsunomiya, T; Yamashita, K; Yoshinaga, K | 1 |
| Arnheim, K | 1 |
| Barber, TD; Kinzler, KW; Velculescu, VE; Vogelstein, B | 1 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Batist, G; Douglas, L; Glenwood, G; Goel, R; Hirte, HW; Jean, M; Lorimer, IA; Mackenzie, MJ; Major, PP; Matthews, S; Miller, WH; Panasci, L; Seymour, L | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Lenz, HJ; Vallbohmer, D | 1 |
| Artale, S; Bardelli, A; Benvenuti, S; Moroni, M; Sartore-Bianchi, A; Siena, S | 1 |
| Friberg, G; Kindler, HL; Skoog, L; Vokes, EE; Wade-Oliver, K | 1 |
| Blanke, CD | 1 |
| Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA | 1 |
| Ganti, AK; Potti, A | 1 |
| Lindner, H; Loeffler-Ragg, J; Lukas, P; Sarg, B; Skvortsov, S; Skvortsova, I; Tabernero, J; Zwierzina, H | 1 |
| Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP | 1 |
| Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S | 1 |
| Benson, AB; Berlin, JD; Coffey, RJ; LaFleur, B; Levy, DE; Morgan-Meadows, SL; Ramanathan, RK; Rothenberg, ML; Washington, MK | 1 |
| Lawrence, TS; Nyati, MK | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Sikic, BI | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Heseltine, D; Meyerhardt, JA; Ogino, S; Ryan, DP; Zhu, AX | 1 |
| Eng, C; Shalan, N | 1 |
| Cunningham, MP; Fan, Z; Modjtahedi, H; Thomas, H | 1 |
| Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX | 1 |
| Botwood, N; Chau, I; Cunningham, D; Hickish, T; Higgins, L; Massey, A; Osborne, R; Swaisland, A | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM | 1 |
| Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L | 1 |
| Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M | 1 |
| Ng, K; Zhu, AX | 1 |
| Ardizzoni, A; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Crocicchio, F; Labianca, R; Mari, E; Pucci, F; Salvagni, S; Scartozzi, M; Sobrero, A; Tagliaferri, P | 1 |
| Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME | 1 |
| Bridgewater, J; Glynne-Jones, R; Harrison, M; Propper, D; Stebbing, J | 1 |
| Biffi, R; Chiappa, A; de Braud, F; Dell'Orto, P; Fazio, N; Magni, E; Monfardini, L; Santoro, L; Sonzogni, A; Zampino, MG; Zorzino, L | 1 |
| Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP | 1 |
| Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ | 1 |
22 review(s) available for gefitinib and Colorectal Cancer
| Article | Year |
|---|---|
Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Disease-Free Survival; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Radiotherapy; Randomized Controlled Trials as Topic | 2019 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Prognostic significance and targeting of HER family in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Panitumumab; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
ZD1839 (Iressa): for more than just non-small cell lung cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
New directions for ZD1839 in the treatment of solid tumors.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Development of ZD1839 in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Angiogenesis and metastasis in colorectal cancer].
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2003 |
[Inhibitors of epidermal growth factor receptor and colorectal cancer].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines | 2004 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Epidermal growth factor receptor as a target for chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Mutation; Neoplasm Metastasis; Panitumumab; Quinazolines | 2008 |
25 trial(s) available for gefitinib and Colorectal Cancer
| Article | Year |
|---|---|
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Quinazolines | 2008 |
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2008 |
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Demography; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Young Adult | 2011 |
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Cycle Proteins; Cell Division; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Cytoskeletal Proteins; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Trans-Activators; Tumor Suppressor Proteins | 2003 |
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Eruptions; Female; Gefitinib; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate; Vomiting | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis | 2005 |
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2006 |
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines | 2007 |
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Male; Middle Aged; Mutation; Quinazolines | 2007 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Disease Progression; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Dropouts; Quinazolines; Time Factors; Treatment Outcome | 2007 |
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate | 2007 |
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Gene Dosage; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Leucovorin; Male; Middle Aged; NF-kappa B; Organoplatinum Compounds; Quinazolines; Survival Rate | 2008 |
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2008 |
A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Pyrimidines; Quinazolines | 2008 |
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Maximum Allowable Concentration; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
44 other study(ies) available for gefitinib and Colorectal Cancer
| Article | Year |
|---|---|
Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines.
Topics: Apoptosis; Caspases; Colorectal Neoplasms; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Mutation; Proto-Oncogene Proteins B-raf; Pyrimidines; ras Proteins; Structure-Activity Relationship | 2012 |
Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Indicators and Reagents; Indoles; Melanoma; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Structure-Activity Relationship; Sulfonamides; Vemurafenib | 2014 |
Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Artemisinins; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3 | 2022 |
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polyglactin 910; Thyroxine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity.
Topics: Adenoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Down-Regulation; Drug Synergism; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Protein Kinase Inhibitors; Receptors, G-Protein-Coupled; Wnt Signaling Pathway | 2018 |
Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticholesteremic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphoproteins; Polyisoprenyl Phosphates; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Simvastatin; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |
Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Enzyme Activation; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Polyglactin 910; Thyroxine; Xenograft Model Antitumor Assays | 2018 |
Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Calcium; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inositol 1,4,5-Trisphosphate Receptors; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins; S-Phase Kinase-Associated Proteins; Thapsigargin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, APC; Humans; Intestinal Mucosa; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Signal Transduction; Triazines | 2019 |
Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Gefitinib; Humans; Quinazolines; Real-Time Polymerase Chain Reaction | 2014 |
Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Mutation; Pemetrexed; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidylate Synthase | 2013 |
Adenomatous polyposis coli determines sensitivity to the EGFR tyrosine kinase inhibitor gefitinib in colorectal cancer cells.
Topics: Adenomatous Polyposis Coli Protein; Antineoplastic Agents; Blotting, Western; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Topics: Animals; Antineoplastic Agents; Butyric Acid; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2014 |
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; ErbB Receptors; Exons; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Mutation; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptor, ErbB-3 | 2015 |
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
Topics: Antibodies, Monoclonal; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Up-Regulation | 2015 |
Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Lysophospholipids; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcriptional Activation | 2016 |
Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer.
Topics: Animals; Apoptosis; Cathepsin B; Cathepsin D; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mitochondria; Pyrans; Quinazolines; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
Topics: Antineoplastic Agents; Carrier Proteins; Cell Line; Cell Line, Tumor; Cell Nucleus; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; HT29 Cells; Humans; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Transcriptional Activation; Up-Regulation | 2015 |
Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail.
Topics: Animals; Azoxymethane; Cell Proliferation; Chemoprevention; Colorectal Neoplasms; Down-Regulation; Epithelial Cells; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Intestinal Mucosa; Lysosomes; Male; Models, Biological; Polyethylene Glycols; Quinazolines; Rats; Rats, Inbred F344; Repressor Proteins; Snail Family Transcription Factors; Transcription Factors; Transcription, Genetic | 2008 |
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Topics: ADAM Proteins; ADAM17 Protein; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Metalloproteases; Quinazolines; Receptor, ErbB-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; src-Family Kinases; TNF-Related Apoptosis-Inducing Ligand; Transforming Growth Factor alpha | 2008 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Gefitinib; Genes, ras; HCT116 Cells; HT29 Cells; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mice, SCID; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2011 |
Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tyrphostins | 2011 |
Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gastritis, Hypertrophic; Gefitinib; Humans; Mice; Neoplasms; Neoplasms, Glandular and Epithelial; Phosphorylation; Prospective Studies; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Heterologous | 2012 |
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epitopes; ErbB Receptors; Gefitinib; Humans; Mutation, Missense; Panitumumab; Quinazolines | 2012 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
On Bayesian methods of exploring qualitative interactions for targeted treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Carboplatin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Computer Simulation; ErbB Receptors; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pharmacogenetics; Quinazolines; Regression Analysis; Survival Analysis | 2012 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
[From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
Topics: Adenomatous Polyposis Coli; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; ErbB Receptors; Follow-Up Studies; Gefitinib; Genes, APC; Genes, DCC; Genes, p53; Genes, ras; Humans; Indoles; Mutation; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Research; Time Factors | 2003 |
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Division; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Nucleus; Colorectal Neoplasms; Cytoplasm; DNA-Binding Proteins; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Matrix Metalloproteinase 7; Middle Aged; Phosphorylation; Protein Transport; Quinazolines; Smad4 Protein; Trans-Activators; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
[Successes in late solid tumors. New therapy offer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Leucovorin; Organoplatinum Compounds; Palliative Care; Quinazolines; Salvage Therapy; Time Factors | 2004 |
Somatic mutations of EGFR in colorectal cancers and glioblastomas.
Topics: Brain Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Glioblastoma; Point Mutation; Quinazolines | 2004 |
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Mutation; Quinazolines | 2005 |
Gefitinib in colorectal cancer: if wishes were horses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Caco-2 Cells; Caspase 3; Caspases; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Serpins | 2005 |
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Antagonism; ErbB Receptors; Fluorouracil; Gefitinib; Gene Expression; Humans; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Hitting the target: measuring EGFR response to tyrosine kinase inhibitors.
Topics: Colon; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines | 2005 |
Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2 | 2006 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate | 2007 |
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.
Topics: Animals; Carcinoma; Cell Division; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Mice; Quinazolines; Radiation-Sensitizing Agents; Transplantation, Heterologous | 2002 |